nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ERBB2—peripheral nervous system neoplasm	0.478	0.874	CbGaD
Afatinib—ABCB1—peripheral nervous system neoplasm	0.0687	0.126	CbGaD
Afatinib—ABCG2—Topotecan—peripheral nervous system neoplasm	0.051	0.214	CbGbCtD
Afatinib—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0354	0.148	CbGbCtD
Afatinib—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0218	0.0912	CbGbCtD
Afatinib—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.0203	0.085	CbGbCtD
Afatinib—ABCG2—Etoposide—peripheral nervous system neoplasm	0.02	0.0835	CbGbCtD
Afatinib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0184	0.077	CbGbCtD
Afatinib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0184	0.077	CbGbCtD
Afatinib—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.0136	0.057	CbGbCtD
Afatinib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0127	0.0534	CbGbCtD
Afatinib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00785	0.0329	CbGbCtD
Afatinib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00732	0.0307	CbGbCtD
Afatinib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00719	0.0301	CbGbCtD
Afatinib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00491	0.0205	CbGbCtD
Afatinib—Gefitinib—CHEK2—peripheral nervous system neoplasm	0.00244	0.892	CrCbGaD
Afatinib—ERBB2—Podofilox—Etoposide—peripheral nervous system neoplasm	0.000418	0.122	CbGdCrCtD
Afatinib—Gefitinib—ABCB1—peripheral nervous system neoplasm	0.000296	0.108	CrCbGaD
Afatinib—DYRK1A—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000283	0.083	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000283	0.083	CbGdCrCtD
Afatinib—DYRK1A—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000283	0.083	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.000262	0.0768	CbGdCrCtD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000262	0.0768	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.000262	0.0768	CbGdCrCtD
Afatinib—ERBB2—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000218	0.0639	CbGdCrCtD
Afatinib—ERBB2—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.0591	CbGdCrCtD
Afatinib—Fatigue—Tretinoin—peripheral nervous system neoplasm	0.000171	0.00151	CcSEcCtD
Afatinib—Fatigue—Isotretinoin—peripheral nervous system neoplasm	0.000171	0.00151	CcSEcCtD
Afatinib—Constipation—Topotecan—peripheral nervous system neoplasm	0.000171	0.00151	CcSEcCtD
Afatinib—Dry eye—Epirubicin—peripheral nervous system neoplasm	0.00017	0.00151	CcSEcCtD
Afatinib—Decreased appetite—Melphalan—peripheral nervous system neoplasm	0.00017	0.00151	CcSEcCtD
Afatinib—Constipation—Tretinoin—peripheral nervous system neoplasm	0.00017	0.0015	CcSEcCtD
Afatinib—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.00017	0.0015	CcSEcCtD
Afatinib—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.000169	0.0015	CcSEcCtD
Afatinib—Fatigue—Melphalan—peripheral nervous system neoplasm	0.000169	0.00149	CcSEcCtD
Afatinib—Eye disorder—Cisplatin—peripheral nervous system neoplasm	0.000169	0.00149	CcSEcCtD
Afatinib—Mouth ulceration—Epirubicin—peripheral nervous system neoplasm	0.000167	0.00147	CcSEcCtD
Afatinib—Bladder pain—Epirubicin—peripheral nervous system neoplasm	0.000167	0.00147	CcSEcCtD
Afatinib—Cystitis noninfective—Doxorubicin—peripheral nervous system neoplasm	0.000167	0.00147	CcSEcCtD
Afatinib—Cystitis—Doxorubicin—peripheral nervous system neoplasm	0.000165	0.00146	CcSEcCtD
Afatinib—Urinary tract disorder—Etoposide—peripheral nervous system neoplasm	0.000163	0.00144	CcSEcCtD
Afatinib—ABL1—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000163	0.0477	CbGdCrCtD
Afatinib—ABL1—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000163	0.0477	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000163	0.0477	CbGdCrCtD
Afatinib—Mediastinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000163	0.00144	CcSEcCtD
Afatinib—Urethral disorder—Etoposide—peripheral nervous system neoplasm	0.000162	0.00143	CcSEcCtD
Afatinib—Infection—Dactinomycin—peripheral nervous system neoplasm	0.000161	0.00142	CcSEcCtD
Afatinib—Cough—Alitretinoin—peripheral nervous system neoplasm	0.000161	0.00142	CcSEcCtD
Afatinib—Sepsis—Epirubicin—peripheral nervous system neoplasm	0.00016	0.00142	CcSEcCtD
Afatinib—Alopecia—Cisplatin—peripheral nervous system neoplasm	0.000159	0.00141	CcSEcCtD
Afatinib—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.000158	0.0014	CcSEcCtD
Afatinib—Dry eye—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.00139	CcSEcCtD
Afatinib—Malnutrition—Cisplatin—peripheral nervous system neoplasm	0.000157	0.00139	CcSEcCtD
Afatinib—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000157	0.00139	CcSEcCtD
Afatinib—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000157	0.00139	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.000156	0.00138	CcSEcCtD
Afatinib—Eye disorder—Etoposide—peripheral nervous system neoplasm	0.000154	0.00137	CcSEcCtD
Afatinib—Mouth ulceration—Doxorubicin—peripheral nervous system neoplasm	0.000154	0.00136	CcSEcCtD
Afatinib—Bladder pain—Doxorubicin—peripheral nervous system neoplasm	0.000154	0.00136	CcSEcCtD
Afatinib—Muscle spasms—Cisplatin—peripheral nervous system neoplasm	0.000151	0.00133	CcSEcCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000151	0.0441	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.000151	0.0441	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.000151	0.0441	CbGdCrCtD
Afatinib—Infection—Alitretinoin—peripheral nervous system neoplasm	0.000149	0.00132	CcSEcCtD
Afatinib—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.000149	0.00132	CcSEcCtD
Afatinib—Sepsis—Doxorubicin—peripheral nervous system neoplasm	0.000148	0.00131	CcSEcCtD
Afatinib—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.000148	0.0013	CcSEcCtD
Afatinib—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000146	0.00129	CcSEcCtD
Afatinib—Alopecia—Etoposide—peripheral nervous system neoplasm	0.000146	0.00129	CcSEcCtD
Afatinib—Infection—Vincristine—peripheral nervous system neoplasm	0.000144	0.00127	CcSEcCtD
Afatinib—Asthenia—Topotecan—peripheral nervous system neoplasm	0.000144	0.00127	CcSEcCtD
Afatinib—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000142	0.00126	CcSEcCtD
Afatinib—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000142	0.00126	CcSEcCtD
Afatinib—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.000142	0.00126	CcSEcCtD
Afatinib—Pruritus—Topotecan—peripheral nervous system neoplasm	0.000142	0.00125	CcSEcCtD
Afatinib—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.000141	0.00125	CcSEcCtD
Afatinib—Dysgeusia—Etoposide—peripheral nervous system neoplasm	0.000141	0.00125	CcSEcCtD
Afatinib—Renal impairment—Epirubicin—peripheral nervous system neoplasm	0.000141	0.00124	CcSEcCtD
Afatinib—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000141	0.00124	CcSEcCtD
Afatinib—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.00014	0.00124	CcSEcCtD
Afatinib—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.00014	0.00124	CcSEcCtD
Afatinib—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.00014	0.00124	CcSEcCtD
Afatinib—Back pain—Etoposide—peripheral nervous system neoplasm	0.000139	0.00123	CcSEcCtD
Afatinib—Pruritus—Melphalan—peripheral nervous system neoplasm	0.000139	0.00123	CcSEcCtD
Afatinib—Muscle spasms—Etoposide—peripheral nervous system neoplasm	0.000138	0.00122	CcSEcCtD
Afatinib—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.000137	0.00121	CcSEcCtD
Afatinib—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.000136	0.0012	CcSEcCtD
Afatinib—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000136	0.0012	CcSEcCtD
Afatinib—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000136	0.0012	CcSEcCtD
Afatinib—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.000134	0.00119	CcSEcCtD
Afatinib—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000134	0.00118	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000133	0.00117	CcSEcCtD
Afatinib—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.000132	0.00117	CcSEcCtD
Afatinib—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000132	0.00117	CcSEcCtD
Afatinib—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000131	0.00116	CcSEcCtD
Afatinib—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000131	0.00116	CcSEcCtD
Afatinib—Insomnia—Vincristine—peripheral nervous system neoplasm	0.000131	0.00116	CcSEcCtD
Afatinib—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000131	0.00116	CcSEcCtD
Afatinib—Renal impairment—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.00115	CcSEcCtD
Afatinib—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.00013	0.00115	CcSEcCtD
Afatinib—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.00013	0.00115	CcSEcCtD
Afatinib—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000129	0.00114	CcSEcCtD
Afatinib—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000128	0.00113	CcSEcCtD
Afatinib—Infection—Cisplatin—peripheral nervous system neoplasm	0.000127	0.00113	CcSEcCtD
Afatinib—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000127	0.00112	CcSEcCtD
Afatinib—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000126	0.00112	CcSEcCtD
Afatinib—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000126	0.00112	CcSEcCtD
Afatinib—Rash—Topotecan—peripheral nervous system neoplasm	0.000126	0.00112	CcSEcCtD
Afatinib—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000126	0.00111	CcSEcCtD
Afatinib—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000126	0.00111	CcSEcCtD
Afatinib—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000126	0.00111	CcSEcCtD
Afatinib—Cough—Etoposide—peripheral nervous system neoplasm	0.000126	0.00111	CcSEcCtD
Afatinib—Headache—Topotecan—peripheral nervous system neoplasm	0.000125	0.00111	CcSEcCtD
Afatinib—Rash—Tretinoin—peripheral nervous system neoplasm	0.000125	0.00111	CcSEcCtD
Afatinib—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000125	0.00111	CcSEcCtD
Afatinib—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000125	0.00111	CcSEcCtD
Afatinib—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000125	0.00111	CcSEcCtD
Afatinib—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000125	0.00111	CcSEcCtD
Afatinib—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000125	0.0011	CcSEcCtD
Afatinib—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000125	0.0011	CcSEcCtD
Afatinib—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000125	0.0011	CcSEcCtD
Afatinib—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000125	0.0011	CcSEcCtD
Afatinib—Headache—Tretinoin—peripheral nervous system neoplasm	0.000124	0.0011	CcSEcCtD
Afatinib—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000124	0.0011	CcSEcCtD
Afatinib—Constipation—Vincristine—peripheral nervous system neoplasm	0.000124	0.0011	CcSEcCtD
Afatinib—Rash—Melphalan—peripheral nervous system neoplasm	0.000124	0.00109	CcSEcCtD
Afatinib—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000123	0.00109	CcSEcCtD
Afatinib—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.000123	0.00109	CcSEcCtD
Afatinib—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.000122	0.00108	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000122	0.00108	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000121	0.00107	CcSEcCtD
Afatinib—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.00012	0.00106	CcSEcCtD
Afatinib—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000119	0.00105	CcSEcCtD
Afatinib—Nausea—Topotecan—peripheral nervous system neoplasm	0.000119	0.00105	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000118	0.00104	CcSEcCtD
Afatinib—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000118	0.00104	CcSEcCtD
Afatinib—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000118	0.00104	CcSEcCtD
Afatinib—Infection—Etoposide—peripheral nervous system neoplasm	0.000117	0.00103	CcSEcCtD
Afatinib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000116	0.00103	CcSEcCtD
Afatinib—Nausea—Melphalan—peripheral nervous system neoplasm	0.000116	0.00103	CcSEcCtD
Afatinib—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.00102	CcSEcCtD
Afatinib—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000115	0.00101	CcSEcCtD
Afatinib—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000114	0.00101	CcSEcCtD
Afatinib—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000114	0.00101	CcSEcCtD
Afatinib—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.001	CcSEcCtD
Afatinib—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000997	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000986	CcSEcCtD
Afatinib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000111	0.000985	CcSEcCtD
Afatinib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000111	0.000981	CcSEcCtD
Afatinib—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000979	CcSEcCtD
Afatinib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000111	0.000978	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000966	CcSEcCtD
Afatinib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000108	0.000954	CcSEcCtD
Afatinib—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000951	CcSEcCtD
Afatinib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000106	0.000941	CcSEcCtD
Afatinib—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000926	CcSEcCtD
Afatinib—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000105	0.000925	CcSEcCtD
Afatinib—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000104	0.000919	CcSEcCtD
Afatinib—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000918	CcSEcCtD
Afatinib—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000912	CcSEcCtD
Afatinib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000912	CcSEcCtD
Afatinib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000103	0.000912	CcSEcCtD
Afatinib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000103	0.00091	CcSEcCtD
Afatinib—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000102	0.000904	CcSEcCtD
Afatinib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000102	0.000902	CcSEcCtD
Afatinib—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000897	CcSEcCtD
Afatinib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000101	0.000896	CcSEcCtD
Afatinib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000101	0.000896	CcSEcCtD
Afatinib—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000101	0.000895	CcSEcCtD
Afatinib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000889	CcSEcCtD
Afatinib—Constipation—Etoposide—peripheral nervous system neoplasm	0.0001	0.000888	CcSEcCtD
Afatinib—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.0001	0.000887	CcSEcCtD
Afatinib—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.0001	0.000887	CcSEcCtD
Afatinib—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	9.95e-05	0.00088	CcSEcCtD
Afatinib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	9.95e-05	0.000879	CcSEcCtD
Afatinib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	9.92e-05	0.000877	CcSEcCtD
Afatinib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	9.76e-05	0.000863	CcSEcCtD
Afatinib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	9.73e-05	0.00086	CcSEcCtD
Afatinib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	9.69e-05	0.000856	CcSEcCtD
Afatinib—Nausea—Dactinomycin—peripheral nervous system neoplasm	9.64e-05	0.000852	CcSEcCtD
Afatinib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	9.61e-05	0.000849	CcSEcCtD
Afatinib—Dizziness—Vincristine—peripheral nervous system neoplasm	9.59e-05	0.000847	CcSEcCtD
Afatinib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	9.57e-05	0.000845	CcSEcCtD
Afatinib—Infestation—Doxorubicin—peripheral nervous system neoplasm	9.55e-05	0.000844	CcSEcCtD
Afatinib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	9.55e-05	0.000844	CcSEcCtD
Afatinib—Rash—Alitretinoin—peripheral nervous system neoplasm	9.49e-05	0.000838	CcSEcCtD
Afatinib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	9.48e-05	0.000838	CcSEcCtD
Afatinib—Headache—Alitretinoin—peripheral nervous system neoplasm	9.42e-05	0.000833	CcSEcCtD
Afatinib—Renal failure—Doxorubicin—peripheral nervous system neoplasm	9.39e-05	0.00083	CcSEcCtD
Afatinib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	9.31e-05	0.000823	CcSEcCtD
Afatinib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	9.28e-05	0.000821	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	9.28e-05	0.00082	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	9.28e-05	0.00082	CcSEcCtD
Afatinib—Vomiting—Vincristine—peripheral nervous system neoplasm	9.22e-05	0.000815	CcSEcCtD
Afatinib—Asthenia—Cisplatin—peripheral nervous system neoplasm	9.2e-05	0.000813	CcSEcCtD
Afatinib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	9.15e-05	0.000809	CcSEcCtD
Afatinib—Rash—Vincristine—peripheral nervous system neoplasm	9.14e-05	0.000808	CcSEcCtD
Afatinib—Dermatitis—Vincristine—peripheral nervous system neoplasm	9.13e-05	0.000807	CcSEcCtD
Afatinib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	9.1e-05	0.000805	CcSEcCtD
Afatinib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	9.08e-05	0.000803	CcSEcCtD
Afatinib—Headache—Vincristine—peripheral nervous system neoplasm	9.08e-05	0.000803	CcSEcCtD
Afatinib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	9.03e-05	0.000798	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	9.01e-05	0.000796	CcSEcCtD
Afatinib—Nausea—Alitretinoin—peripheral nervous system neoplasm	8.94e-05	0.00079	CcSEcCtD
Afatinib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	8.77e-05	0.000775	CcSEcCtD
Afatinib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	8.66e-05	0.000765	CcSEcCtD
Afatinib—Nausea—Vincristine—peripheral nervous system neoplasm	8.61e-05	0.000761	CcSEcCtD
Afatinib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	8.47e-05	0.000748	CcSEcCtD
Afatinib—Asthenia—Etoposide—peripheral nervous system neoplasm	8.43e-05	0.000745	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	8.42e-05	0.000745	CcSEcCtD
Afatinib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	8.4e-05	0.000743	CcSEcCtD
Afatinib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	8.35e-05	0.000738	CcSEcCtD
Afatinib—Pruritus—Etoposide—peripheral nervous system neoplasm	8.31e-05	0.000734	CcSEcCtD
Afatinib—Alopecia—Epirubicin—peripheral nervous system neoplasm	8.19e-05	0.000724	CcSEcCtD
Afatinib—Vomiting—Cisplatin—peripheral nervous system neoplasm	8.15e-05	0.00072	CcSEcCtD
Afatinib—Mental disorder—Epirubicin—peripheral nervous system neoplasm	8.12e-05	0.000717	CcSEcCtD
Afatinib—Rash—Cisplatin—peripheral nervous system neoplasm	8.08e-05	0.000714	CcSEcCtD
Afatinib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	8.07e-05	0.000714	CcSEcCtD
Afatinib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	8.07e-05	0.000713	CcSEcCtD
Afatinib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	8.03e-05	0.00071	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	8.01e-05	0.000708	CcSEcCtD
Afatinib—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	7.9e-05	0.000698	CcSEcCtD
Afatinib—Back pain—Epirubicin—peripheral nervous system neoplasm	7.8e-05	0.00069	CcSEcCtD
Afatinib—Dizziness—Etoposide—peripheral nervous system neoplasm	7.77e-05	0.000686	CcSEcCtD
Afatinib—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	7.75e-05	0.000685	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	7.73e-05	0.000683	CcSEcCtD
Afatinib—Nausea—Cisplatin—peripheral nervous system neoplasm	7.61e-05	0.000673	CcSEcCtD
Afatinib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	7.58e-05	0.00067	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	7.51e-05	0.000664	CcSEcCtD
Afatinib—Vomiting—Etoposide—peripheral nervous system neoplasm	7.47e-05	0.00066	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	7.46e-05	0.00066	CcSEcCtD
Afatinib—Rash—Etoposide—peripheral nervous system neoplasm	7.4e-05	0.000654	CcSEcCtD
Afatinib—Dermatitis—Etoposide—peripheral nervous system neoplasm	7.4e-05	0.000654	CcSEcCtD
Afatinib—Headache—Etoposide—peripheral nervous system neoplasm	7.36e-05	0.00065	CcSEcCtD
Afatinib—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	7.31e-05	0.000646	CcSEcCtD
Afatinib—Back pain—Doxorubicin—peripheral nervous system neoplasm	7.22e-05	0.000638	CcSEcCtD
Afatinib—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	7.17e-05	0.000634	CcSEcCtD
Afatinib—Cough—Epirubicin—peripheral nervous system neoplasm	7.04e-05	0.000622	CcSEcCtD
Afatinib—Nausea—Etoposide—peripheral nervous system neoplasm	6.98e-05	0.000617	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	6.82e-05	0.000603	CcSEcCtD
Afatinib—Infection—Epirubicin—peripheral nervous system neoplasm	6.54e-05	0.000578	CcSEcCtD
Afatinib—Cough—Doxorubicin—peripheral nervous system neoplasm	6.51e-05	0.000576	CcSEcCtD
Afatinib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	6.46e-05	0.000571	CcSEcCtD
Afatinib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	6.39e-05	0.000565	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	6.31e-05	0.000558	CcSEcCtD
Afatinib—Infection—Doxorubicin—peripheral nervous system neoplasm	6.05e-05	0.000535	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	5.97e-05	0.000528	CcSEcCtD
Afatinib—Insomnia—Epirubicin—peripheral nervous system neoplasm	5.95e-05	0.000526	CcSEcCtD
Afatinib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	5.92e-05	0.000523	CcSEcCtD
Afatinib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	5.87e-05	0.000519	CcSEcCtD
Afatinib—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	5.79e-05	0.000512	CcSEcCtD
Afatinib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	5.72e-05	0.000506	CcSEcCtD
Afatinib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	5.68e-05	0.000502	CcSEcCtD
Afatinib—Fatigue—Epirubicin—peripheral nervous system neoplasm	5.68e-05	0.000502	CcSEcCtD
Afatinib—Constipation—Epirubicin—peripheral nervous system neoplasm	5.63e-05	0.000498	CcSEcCtD
Afatinib—Insomnia—Doxorubicin—peripheral nervous system neoplasm	5.51e-05	0.000487	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	5.43e-05	0.00048	CcSEcCtD
Afatinib—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	5.36e-05	0.000474	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	5.29e-05	0.000468	CcSEcCtD
Afatinib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	5.26e-05	0.000465	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	5.25e-05	0.000464	CcSEcCtD
Afatinib—Constipation—Doxorubicin—peripheral nervous system neoplasm	5.21e-05	0.00046	CcSEcCtD
Afatinib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	5.2e-05	0.00046	CcSEcCtD
Afatinib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	4.81e-05	0.000426	CcSEcCtD
Afatinib—Asthenia—Epirubicin—peripheral nervous system neoplasm	4.72e-05	0.000417	CcSEcCtD
Afatinib—Pruritus—Epirubicin—peripheral nervous system neoplasm	4.66e-05	0.000412	CcSEcCtD
Afatinib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	4.5e-05	0.000398	CcSEcCtD
Afatinib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	4.37e-05	0.000386	CcSEcCtD
Afatinib—Dizziness—Epirubicin—peripheral nervous system neoplasm	4.35e-05	0.000385	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	4.31e-05	0.000381	CcSEcCtD
Afatinib—Vomiting—Epirubicin—peripheral nervous system neoplasm	4.19e-05	0.00037	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	4.17e-05	0.000368	CcSEcCtD
Afatinib—Rash—Epirubicin—peripheral nervous system neoplasm	4.15e-05	0.000367	CcSEcCtD
Afatinib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	4.15e-05	0.000367	CcSEcCtD
Afatinib—Headache—Epirubicin—peripheral nervous system neoplasm	4.12e-05	0.000364	CcSEcCtD
Afatinib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	4.03e-05	0.000356	CcSEcCtD
Afatinib—Nausea—Epirubicin—peripheral nervous system neoplasm	3.91e-05	0.000346	CcSEcCtD
Afatinib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	3.87e-05	0.000342	CcSEcCtD
Afatinib—Rash—Doxorubicin—peripheral nervous system neoplasm	3.84e-05	0.000339	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	3.84e-05	0.000339	CcSEcCtD
Afatinib—Headache—Doxorubicin—peripheral nervous system neoplasm	3.82e-05	0.000337	CcSEcCtD
Afatinib—Nausea—Doxorubicin—peripheral nervous system neoplasm	3.62e-05	0.00032	CcSEcCtD
Afatinib—EGFR—EGF/EGFR Signaling Pathway—AKT1—peripheral nervous system neoplasm	1.72e-05	0.000181	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	1.72e-05	0.000181	CbGpPWpGaD
Afatinib—LCK—Hemostasis—PTPN11—peripheral nervous system neoplasm	1.72e-05	0.000181	CbGpPWpGaD
Afatinib—EGFR—Focal Adhesion—HRAS—peripheral nervous system neoplasm	1.72e-05	0.000181	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	1.71e-05	0.000181	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	1.71e-05	0.00018	CbGpPWpGaD
Afatinib—EGFR—DAP12 signaling—AKT1—peripheral nervous system neoplasm	1.71e-05	0.00018	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—NRAS—peripheral nervous system neoplasm	1.69e-05	0.000178	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.68e-05	0.000177	CbGpPWpGaD
Afatinib—EGFR—B Cell Activation—HRAS—peripheral nervous system neoplasm	1.68e-05	0.000177	CbGpPWpGaD
Afatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	1.68e-05	0.000177	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—ERBB2—peripheral nervous system neoplasm	1.68e-05	0.000177	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.68e-05	0.000177	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	1.67e-05	0.000176	CbGpPWpGaD
Afatinib—LCK—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	1.67e-05	0.000176	CbGpPWpGaD
Afatinib—EGFR—Immune System—IFNB1—peripheral nervous system neoplasm	1.66e-05	0.000175	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	1.66e-05	0.000175	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—NRAS—peripheral nervous system neoplasm	1.66e-05	0.000175	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—HRAS—peripheral nervous system neoplasm	1.65e-05	0.000174	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	1.65e-05	0.000174	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—AKT1—peripheral nervous system neoplasm	1.64e-05	0.000173	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—AKT1—peripheral nervous system neoplasm	1.64e-05	0.000172	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—NRAS—peripheral nervous system neoplasm	1.63e-05	0.000172	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—HRAS—peripheral nervous system neoplasm	1.62e-05	0.000171	CbGpPWpGaD
Afatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	1.62e-05	0.000171	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.62e-05	0.00017	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	1.61e-05	0.00017	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—PTPN11—peripheral nervous system neoplasm	1.61e-05	0.000169	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—AKT1—peripheral nervous system neoplasm	1.61e-05	0.000169	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	1.61e-05	0.000169	CbGpPWpGaD
Afatinib—EGFR—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	1.61e-05	0.000169	CbGpPWpGaD
Afatinib—LCK—Immune System—IFNB1—peripheral nervous system neoplasm	1.6e-05	0.000169	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	1.59e-05	0.000168	CbGpPWpGaD
Afatinib—PHKG2—Disease—HRAS—peripheral nervous system neoplasm	1.59e-05	0.000167	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	1.58e-05	0.000166	CbGpPWpGaD
Afatinib—EGFR—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	1.57e-05	0.000165	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	1.56e-05	0.000164	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	1.55e-05	0.000163	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	1.55e-05	0.000163	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.55e-05	0.000163	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PTPN11—peripheral nervous system neoplasm	1.55e-05	0.000163	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	1.55e-05	0.000163	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—AKT1—peripheral nervous system neoplasm	1.55e-05	0.000163	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	1.55e-05	0.000163	CbGpPWpGaD
Afatinib—EGFR—Disease—SLC2A1—peripheral nervous system neoplasm	1.54e-05	0.000163	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	1.54e-05	0.000162	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	1.53e-05	0.000161	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—NRAS—peripheral nervous system neoplasm	1.53e-05	0.000161	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	1.52e-05	0.00016	CbGpPWpGaD
Afatinib—EGFR—Focal Adhesion—AKT1—peripheral nervous system neoplasm	1.52e-05	0.00016	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	1.51e-05	0.000159	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.51e-05	0.000159	CbGpPWpGaD
Afatinib—ERBB4—Immune System—ERBB2—peripheral nervous system neoplasm	1.51e-05	0.000159	CbGpPWpGaD
Afatinib—ABL1—Immune System—HGF—peripheral nervous system neoplasm	1.5e-05	0.000158	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ENO2—peripheral nervous system neoplasm	1.5e-05	0.000158	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.49e-05	0.000157	CbGpPWpGaD
Afatinib—LCK—Disease—SLC2A1—peripheral nervous system neoplasm	1.49e-05	0.000157	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.49e-05	0.000157	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	1.49e-05	0.000157	CbGpPWpGaD
Afatinib—EGFR—B Cell Activation—AKT1—peripheral nervous system neoplasm	1.49e-05	0.000156	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—ERBB2—peripheral nervous system neoplasm	1.49e-05	0.000156	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.47e-05	0.000155	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.46e-05	0.000154	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—AKT1—peripheral nervous system neoplasm	1.46e-05	0.000154	CbGpPWpGaD
Afatinib—BLK—Immune System—ERBB2—peripheral nervous system neoplasm	1.45e-05	0.000153	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—NRAS—peripheral nervous system neoplasm	1.44e-05	0.000152	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.44e-05	0.000152	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—ERBB2—peripheral nervous system neoplasm	1.44e-05	0.000151	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—AKT1—peripheral nervous system neoplasm	1.43e-05	0.000151	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	1.42e-05	0.00015	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.42e-05	0.000149	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	1.41e-05	0.000148	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.4e-05	0.000148	CbGpPWpGaD
Afatinib—PHKG2—Disease—AKT1—peripheral nervous system neoplasm	1.4e-05	0.000147	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PTPN11—peripheral nervous system neoplasm	1.4e-05	0.000147	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.39e-05	0.000147	CbGpPWpGaD
Afatinib—ERBB4—Disease—ERBB2—peripheral nervous system neoplasm	1.39e-05	0.000146	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.38e-05	0.000146	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	1.37e-05	0.000144	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	1.34e-05	0.000141	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.33e-05	0.00014	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—HRAS—peripheral nervous system neoplasm	1.31e-05	0.000138	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.3e-05	0.000137	CbGpPWpGaD
Afatinib—LCK—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	1.3e-05	0.000136	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.29e-05	0.000136	CbGpPWpGaD
Afatinib—EGFR—Immune System—HGF—peripheral nervous system neoplasm	1.28e-05	0.000135	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	1.28e-05	0.000135	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—NRAS—peripheral nervous system neoplasm	1.28e-05	0.000135	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.27e-05	0.000134	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—ERBB2—peripheral nervous system neoplasm	1.27e-05	0.000134	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—BCHE—peripheral nervous system neoplasm	1.27e-05	0.000133	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—NRAS—peripheral nervous system neoplasm	1.26e-05	0.000132	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.25e-05	0.000132	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.24e-05	0.00013	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—HRAS—peripheral nervous system neoplasm	1.24e-05	0.00013	CbGpPWpGaD
Afatinib—LCK—Immune System—HGF—peripheral nervous system neoplasm	1.24e-05	0.00013	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	1.23e-05	0.00013	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.23e-05	0.00013	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—ERBB2—peripheral nervous system neoplasm	1.22e-05	0.000129	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.22e-05	0.000129	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	1.22e-05	0.000128	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—HRAS—peripheral nervous system neoplasm	1.21e-05	0.000128	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.21e-05	0.000127	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—HRAS—peripheral nervous system neoplasm	1.19e-05	0.000126	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—TH—peripheral nervous system neoplasm	1.19e-05	0.000125	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	1.17e-05	0.000124	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.17e-05	0.000124	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—AKT1—peripheral nervous system neoplasm	1.17e-05	0.000123	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.16e-05	0.000123	CbGpPWpGaD
Afatinib—ERBB2—Immune System—NRAS—peripheral nervous system neoplasm	1.16e-05	0.000123	CbGpPWpGaD
Afatinib—ERBB4—Immune System—NRAS—peripheral nervous system neoplasm	1.15e-05	0.000121	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—NRAS—peripheral nervous system neoplasm	1.13e-05	0.000119	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.12e-05	0.000118	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.12e-05	0.000118	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—HRAS—peripheral nervous system neoplasm	1.12e-05	0.000118	CbGpPWpGaD
Afatinib—IRAK1—Immune System—ERBB2—peripheral nervous system neoplasm	1.11e-05	0.000116	CbGpPWpGaD
Afatinib—BLK—Immune System—NRAS—peripheral nervous system neoplasm	1.1e-05	0.000116	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.1e-05	0.000116	CbGpPWpGaD
Afatinib—ABL1—Immune System—PTPN11—peripheral nervous system neoplasm	1.09e-05	0.000115	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—AKT1—peripheral nervous system neoplasm	1.09e-05	0.000115	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—NRAS—peripheral nervous system neoplasm	1.09e-05	0.000115	CbGpPWpGaD
Afatinib—ERBB2—Disease—NRAS—peripheral nervous system neoplasm	1.07e-05	0.000113	CbGpPWpGaD
Afatinib—ERBB4—Disease—NRAS—peripheral nervous system neoplasm	1.06e-05	0.000111	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.06e-05	0.000111	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—AKT1—peripheral nervous system neoplasm	1.05e-05	0.000111	CbGpPWpGaD
Afatinib—LCK—Hemostasis—NRAS—peripheral nervous system neoplasm	1.03e-05	0.000109	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.02e-05	0.000108	CbGpPWpGaD
Afatinib—ERBB2—Disease—MYC—peripheral nervous system neoplasm	1e-05	0.000105	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KNG1—peripheral nervous system neoplasm	9.95e-06	0.000105	CbGpPWpGaD
Afatinib—ERBB4—Disease—MYC—peripheral nervous system neoplasm	9.86e-06	0.000104	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	9.74e-06	0.000103	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	9.72e-06	0.000102	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—NRAS—peripheral nervous system neoplasm	9.66e-06	0.000102	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—peripheral nervous system neoplasm	9.6e-06	0.000101	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KNG1—peripheral nervous system neoplasm	9.59e-06	0.000101	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	9.53e-06	0.0001	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	9.48e-06	9.99e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—HRAS—peripheral nervous system neoplasm	9.36e-06	9.86e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PTPN11—peripheral nervous system neoplasm	9.35e-06	9.85e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—AKT1—peripheral nervous system neoplasm	9.33e-06	9.82e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—NRAS—peripheral nervous system neoplasm	9.31e-06	9.8e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	9.27e-06	9.77e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—HRAS—peripheral nervous system neoplasm	9.18e-06	9.67e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	9.14e-06	9.63e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	9.04e-06	9.52e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	9.03e-06	9.51e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PTPN11—peripheral nervous system neoplasm	9.01e-06	9.49e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	8.97e-06	9.45e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	8.94e-06	9.41e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CASP3—peripheral nervous system neoplasm	8.84e-06	9.31e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—GNAS—peripheral nervous system neoplasm	8.7e-06	9.16e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—ERBB2—peripheral nervous system neoplasm	8.65e-06	9.11e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTPN11—peripheral nervous system neoplasm	8.64e-06	9.09e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HRAS—peripheral nervous system neoplasm	8.51e-06	8.96e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—NRAS—peripheral nervous system neoplasm	8.41e-06	8.86e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—GNAS—peripheral nervous system neoplasm	8.39e-06	8.83e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HRAS—peripheral nervous system neoplasm	8.38e-06	8.83e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTPN11—peripheral nervous system neoplasm	8.32e-06	8.76e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.27e-06	8.71e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—AKT1—peripheral nervous system neoplasm	8.27e-06	8.7e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—AKT1—peripheral nervous system neoplasm	8.11e-06	8.54e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	8.1e-06	8.53e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—HRAS—peripheral nervous system neoplasm	8.07e-06	8.49e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—HRAS—peripheral nervous system neoplasm	8e-06	8.42e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—peripheral nervous system neoplasm	7.91e-06	8.33e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—HRAS—peripheral nervous system neoplasm	7.86e-06	8.28e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—HRAS—peripheral nervous system neoplasm	7.74e-06	8.15e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	7.62e-06	8.03e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—HRAS—peripheral nervous system neoplasm	7.56e-06	7.96e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.52e-06	7.92e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—AKT1—peripheral nervous system neoplasm	7.52e-06	7.91e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.41e-06	7.8e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—AKT1—peripheral nervous system neoplasm	7.4e-06	7.8e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—ERBB2—peripheral nervous system neoplasm	7.39e-06	7.79e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.3e-06	7.69e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.15e-06	7.53e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ERBB2—peripheral nervous system neoplasm	7.12e-06	7.5e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—AKT1—peripheral nervous system neoplasm	7.12e-06	7.5e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HRAS—peripheral nervous system neoplasm	7.06e-06	7.44e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—AKT1—peripheral nervous system neoplasm	7.06e-06	7.44e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.01e-06	7.38e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—AKT1—peripheral nervous system neoplasm	6.94e-06	7.31e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.9e-06	7.27e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	6.84e-06	7.21e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—AKT1—peripheral nervous system neoplasm	6.83e-06	7.2e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—ERBB2—peripheral nervous system neoplasm	6.83e-06	7.19e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—peripheral nervous system neoplasm	6.81e-06	7.17e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	6.78e-06	7.14e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—peripheral nervous system neoplasm	6.68e-06	7.03e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—NRAS—peripheral nervous system neoplasm	6.58e-06	6.93e-05	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB2—peripheral nervous system neoplasm	6.58e-06	6.93e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	6.54e-06	6.88e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.53e-06	6.88e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.49e-06	6.83e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	6.44e-06	6.78e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—peripheral nervous system neoplasm	6.24e-06	6.57e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.16e-06	6.48e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—peripheral nervous system neoplasm	6.15e-06	6.48e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.05e-06	6.37e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—peripheral nervous system neoplasm	6.01e-06	6.33e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5.99e-06	6.31e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.83e-06	6.14e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5.77e-06	6.08e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.75e-06	6.06e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.67e-06	5.97e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—NRAS—peripheral nervous system neoplasm	5.62e-06	5.92e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.5e-06	5.8e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.44e-06	5.73e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—peripheral nervous system neoplasm	5.43e-06	5.72e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.42e-06	5.71e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NRAS—peripheral nervous system neoplasm	5.42e-06	5.71e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	5.25e-06	5.53e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NRAS—peripheral nervous system neoplasm	5.19e-06	5.47e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.07e-06	5.33e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NRAS—peripheral nervous system neoplasm	5e-06	5.27e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.86e-06	5.12e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—peripheral nervous system neoplasm	4.84e-06	5.09e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—peripheral nervous system neoplasm	4.82e-06	5.07e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.79e-06	5.04e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.78e-06	5.03e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—peripheral nervous system neoplasm	4.66e-06	4.91e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.61e-06	4.85e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.5e-06	4.74e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.34e-06	4.57e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—peripheral nervous system neoplasm	4.25e-06	4.48e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.18e-06	4.4e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.16e-06	4.38e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—peripheral nervous system neoplasm	4.11e-06	4.33e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.98e-06	4.19e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.98e-06	4.19e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—peripheral nervous system neoplasm	3.97e-06	4.18e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—peripheral nervous system neoplasm	3.8e-06	4e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—peripheral nervous system neoplasm	3.66e-06	3.86e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.64e-06	3.83e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—peripheral nervous system neoplasm	3.63e-06	3.83e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.51e-06	3.7e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.5e-06	3.69e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—peripheral nervous system neoplasm	3.5e-06	3.69e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.39e-06	3.57e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—peripheral nervous system neoplasm	3.35e-06	3.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.26e-06	3.44e-05	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—peripheral nervous system neoplasm	3.23e-06	3.4e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.78e-06	2.93e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.68e-06	2.82e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.66e-06	2.8e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	2.62e-06	2.76e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.56e-06	2.7e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.35e-06	2.47e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.26e-06	2.38e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	1.42e-06	1.49e-05	CbGpPWpGaD
